[1] 中华医学会肝病学分会,中华医学会感染病学分会.慢性乙型肝炎防治指南(2015年更新版),临床肝胆病杂志,2015,31:1941-1960.
[2] 崔富强,庄辉,我国乙型肝炎防控工作进展、挑战及对策.中国病毒病杂志,2016,6:81-87.
[3] Zhang S,Ma Q,Liang S,et al. Annual economic burden of hepatitis B virus-related diseases among hospitalized patients in twelve cities in China.J Viral Hepat,2016,233:202-210.
[4] European Association for the Study of the Liver.EASL2017 Clinical Practice Guidelines on the management of hepatitis B virus infection.J Hepatol,2017,67:370-398.
[5] 胡敏鹂,郑琦,江家骥.乙型病毒性肝炎的免疫动力学.世界华人消化杂志,2011,19:1381-1388.
[6] 黄道,朱韧,张欣欣.慢性乙型肝炎免疫发病机制及免疫治疗.中国病毒病杂志,2013,3:233-237.
[7] Ratnam DT,Sievert W,Visvanathan K.Natural killer cells display impaired responses to toll like receptor 9 that support viral persistence in chronic hepatitis B.Cell Immunol,2012,279:109-115.
[8] Lobaina Y,Michel ML.Chronic hepatitis B:Immunological profile and current therapeutic vaccines in clinical trials.Vaccine,2017,35:2308-2314.
[9] Maini MK,Boni C,Lee CK,et al.The role of virus-specific CD8(+) cells in liver damage and viral control during persistent hepatitis B virus infection.J Exp Med.,2000,191:1269-1280.
[10] 胡晨波,方敏,陈晓蓉,等.慢性乙型肝炎前C区和基本核心启动子突变的临床意义.肝脏,2013,18:579-581.
[11] 荣义辉,辛绍杰.乙型肝炎病毒S区基因变异研究进展.肝脏,2013,18:779-781.
[12] 许倩,于晓辉,吴雄志,等.乙型肝炎病毒免疫逃逸机制研究.中国综合临床,2004,20:861-863.
[13] Chang KM,Liu M.Chronic hepatitis B:immune pathogenesis and emerging immunotherapeutics.Curr Opin Pharmacol,2016,30:93-105.
[14] Michalak TI.Occult persistence and lymphotropism of hepadnaviral infection: insights from the woodchuck viral hepatitis model.Immunol Rew,2000,174:98-111.
[15] Park JS,Pan CQ.Viral factors for HBV mother-to-child transmission.Hepatol Int,2017, 12.
[16] 张欣欣课题组在乙型肝炎病毒免疫逃逸研究方面取得重要成果.上海交通大学学报(医学版),2015,35:1761.
[17] World Health Organization.Guidelines for the prevention,care and treatmentof persons with chronic hepatitis B infection.2015.
[18] Sarin SK,Kumar M,Lau GK,et al.Asian-Pacific clinical practice guidelines on the management of hepatitis B:a 2015 update.Hepatol Int,2016,10:1-98.
[19] Terrault NA,Bzowej NH,Chang KM,et al.American Association for the Study of Liver Diseases.AASLD guidelines for treatment of chronic hepatitis B.Hepatology.2016,63:261-283.
[20] Gaia S,Marzano A,Olivero A,et al.Inactive hepatitis B virus carriers:a favourable clinical condition.Eur J Gastroenterol Hepatol,2005,17:1435-1436.
[21] 黄珊,何清,唐奇远,等.91例非活动性HBsAg携带者肝组织病理特点的研究.中国病毒病杂志,2012,2:58-61.
[22] 刘启材,林思炜,何浩岚,等.低病毒载量HBeAg阴性慢性乙型肝炎患者肝纤维化特征分析.中华实验和临床感染病杂志(电子版),2015,9:186-190.
[23] Liao B,Wang Z,Lin S,et al.Significant fibrosis is not rare in Chinese chronic hepatitis B patients with persistent normal ALT.PLoS One,2013,8:e78672.
[24] 何卫平,陈婧,胡瑾华,等.非活动性HBsAg携带者临床病理分析.临床肝胆病杂志,2008,24:22-23.
[25] 艾香英,符林春,范慧敏,等.35例HBeAg阴性慢性乙型肝炎患者肝组织病理学分析.实用肝脏病杂志,2013,16:122-124.
[26] 刘志华,何海棠,胡静,等.HBeAg阴性慢性乙型肝炎患者肝脏病理改变及相关因素分析.实用医学杂志,2015,31:2626-2630.
[27] 何清.中国慢性HBV感染自然史各期肝组织病理特点及HBcAg分布规律的研究.中华医学会感染病学分会、中华医学会肝病学分会.中华医学会第十六次全国病毒性肝炎及肝病学术会议论文汇编.中华医学会感染病学分会、中华医学会肝病学分会,2013:2.
[28] Invernizzi F,Viganò M,Grossi G,et al.The prognosis and management of inactive HBV carriers.Liver Int,2016,36:100-404.
[29] 任婷婷,徐光华,李春霞,等.非活动性HBsAg携带状态的自然转归.肝脏,2014,19:71-73. |
